BILLERICA, Mass.--(BUSINESS WIRE)--
Bruker (NASDAQ: BRKR) today announced five orders for ultra-high field
(UHF) nuclear magnetic resonance (NMR) spectroscopy systems from Europe
and Brazil in recent months. These UHF systems have been funded for
cutting-edge NMR research in structural biology, intrinsically
disordered proteins (IDPs), membrane proteins, macro-molecular complexes
and interactions, cell biology, disease research, as well as in advanced
materials research.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20150917005142/en/
Next generation Aeon 1.2 GHz NMR system (Photo: Business Wire).
Bruker defines UHF as NMR systems with 1H proton frequency of
900 MHz or above. Other high-field 700, 800 and 850 MHz orders are not
included in the UHF definition. The recent UHF NMR orders include three
900 and 950 MHz systems from Brazil, Switzerland and the UK, with
revenue typically within 18 months from order:
-
The Federal University of Rio de Janeiro (UFRJ) in Brazil is
expanding its existing structural biology facility with the addition
of a 900 MHz NMR spectrometer. As one of the leading universities in
South America, the new 900 MHz system will be available as a regional
resource for research in protein structure and dynamics, protein
folding and structure of nucleic acids. Professor Fabio C. L. Almeida
of UFRJ commented: "Having a 900 MHz will have a strong impact on the
development of NMR and structural biology in Brazil and Latin America.
It will offer us advantages and capabilities over other techniques in
tackling important biological and technological problems."
-
The École Polytechnique Féderale de Lausanne (EPFL) in
Switzerland has ordered a Bruker 900 MHz instrument with the highest
field wide-bore (89 mm inner diameter) magnet currently available for
solid-state NMR. It will enable EPFL researchers to tackle problems in
complex systems such as enzymes, catalytic nanoparticles, active
pharmaceutical ingredients and live model organisms.
-
The University of Leeds in the UK is expanding its Astbury
Centre for Structural Molecular Biology with a 950 MHz NMR equipped
with a novel CryoProbe that is now designed for both 13C
and 15N direct detection, besides traditional 1H
indirect detection. This technology makes the instrument suitable for
determining structures, dynamics and interactions of globular
proteins, as well as for advanced functional and disease mechanism
studies of intrinsically disordered proteins (IDPs). Professor Alex
Breeze at the University of Leeds stated: “We are tremendously excited
to be installing our new 950 MHz instrument, which will complement our
investment in cutting-edge cryo-electron microscopy and other
structural techniques. In particular, the combination of 950 MHz field
strength and the novel direct-detection and low-volume capabilities of
the latest CryoProbes will allow us to access critical
structural and dynamic information on important biological systems and
medically relevant targets with the optimum sensitivity and
resolution.”
In 2015, Bruker also has received two additional orders for
next-generation GHz-class systems from France and Germany, and Bruker’s
backlog for GHz-class NMR systems has now increased to nine (9) systems
for different European and Canadian customers. Bruker expects to begin
to recognize revenues from next-generation Aeon™ 1.0 GHz
systems in 2016. The Aeon 1.2 GHz systems backlog
is projected to ship over several years, starting in late 2017 or 2018.
Revenue timing for future 1.2 GHz systems has inherent risks, and
depends on further progress in high-temperature superconductor (HTS)
materials and HTS-based NMR magnet technology.
-
A 1.2 GHz instrument ordered by the CNRS is expected to be placed at
the University of Lille in France and will be available to the
French and European scientific community through the NMR Large Scale
Facility, hosted by the Centre National de la Recherche Scientifique
(CNRS). Dr. Jean-Pierre Simorre, Director of the Large Scale Facility,
explained: “The acquisition of this 1.2 GHz spectrometer will keep
France at the leading edge of NMR technology. This national instrument
will be installed in Lille for a broad panel of interdisciplinary
research areas ranging from structural biology to catalysis, from
sustainable energy development to bio-medical applications.”
-
The Center for Biomolecular Magnetic Resonance (BMRZ) at the Goethe
University in Frankfurt, Germany is part of the European Large
Scale Facilities and incorporates various high-field liquid and
solid-state NMR spectrometers, as well as DNP-NMR and EPR
instrumentation. The 1.2 GHz NMR ordered recently is expected to be
available to the scientific community in Germany and Europe. Research
at the BMRZ is dedicated to the elucidation of structure and
functional mechanisms of biomolecules ranging from RNA and RNA-protein
complexes, via large protein complexes to membrane proteins. Professor
Harald Schwalbe from the BMRZ remarked: "We are very happy to have
placed the order for the next generation of NMR. The 1.2 GHz NMR
system will allow us to investigate structure, dynamics and biological
function of increasingly large and challenging biomolecular complexes.
We will also be able to provide access for European researchers."
Forward-Looking Statements
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by the use of words such as
“anticipate,” “believe,” “expect,” “will,” “may,” “estimate,” “plan,”
“outlook,” and “project” and other similar expressions that predict or
indicate future events or trends or that are not statements of
historical matters. Such forward-looking statements reflect the views of
management at the time such statements are made and are subject to a
number of risks, uncertainties, estimates, and assumptions that may
cause actual results to differ materially from current expectations.
These statements include our expectations related to the production and
delivery of technologically advanced UHF NMR systems and the amount and
timing of future revenues from UHF NMR systems orders currently in our
backlog. Although we believe the assumptions upon which these
forward-looking statements are based are reasonable, any of these
assumptions could prove to be inaccurate and the forward-looking
statements based on these assumptions could be incorrect. Our actual
future performance may differ materially from such expectations as a
result of important risk factors, which include, in addition to those
identified in the our Annual Report on Form 10-K for the year ended
December 31, 2014 and our other subsequent filings with the Securities
and Exchange Commission, risks and uncertainties associated with our
ability to develop high-temperature superconductor (HTS) materials and
HTS-based magnets required for 1.2 GHz NMR systems. These risks and
uncertainties could cause actual results to differ materially from those
stated or implied in these forward-looking statements. We expressly
disclaim any obligation to update or revise these forward-looking
statements, except as required by law or regulation.
About Bruker Corporation (NASDAQ: BRKR)
For more than 50 years, Bruker has enabled scientists to make
breakthrough discoveries and develop new applications that improve the
quality of human life. Bruker’s high-performance scientific research
instruments and high-value analytical solutions enable scientists to
explore life and materials at molecular, cellular and microscopic levels.
In close cooperation with our customers, Bruker is enabling innovation,
productivity and customer success in life science molecular research, in
applied and pharma applications, in microscopy, nano-analysis and
industrial applications, as well as in cell biology, preclinical
imaging, clinical research, microbiology and molecular diagnostics. For
more information, please visit www.bruker.com.
For more information on Bruker, please visit www.bruker.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20150917005142/en/
Source: Bruker Corporation